Development of Amoxicillin-Loaded Modified Polycaprolactone Microparticles in Medical Application

Chalita Metheeparakornchai¹, Narumol Kreua-ongarjnukool¹, Saowapa Thumsing Niyomthai¹, Prasit Pavasant²,³,⁴ and Chalida Nakalekha Limjeerajarus⁴

¹Department of Industrial Chemistry, Faculty of Applied Science, King Mongkut’s University of Technology North Bangkok, Thailand
²Excellence Center in Regenerative Dentistry, Thailand
³Mineralized Tissue Research Unit, Thailand
⁴Department of Anatomy, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand

Email: chalita.mpc@gmail.com, {narumol.k, saowapa.t}@sci.kmutnb.ac.th

Abstract—Amoxicillin is realized as significant drug due to their essential inhibition of bacterial infections. However, the effective time of amoxicillin in clinical position is less than 8 hours. Therefore, this research was to prolong the drug delivery system. Chitosan was modified by PCL (PCL/CS) microparticles were fabricated by oil in water emulsion (o/w emulsion) techniques for the protection and controlled the release of amoxicillin. The ratio of PCL: chitosan at different ratios were investigated for their influences on the zeta potential, size, morphology, swelling ratio and the release rate of amoxicillin from PCL/CS microparticles. The encapsulation efficiency was 74% to 83% and the maximum cumulative released amounts of amoxicillin from the PCL/CS at ratio 1:5 was about 6.5±0.03 mg for 7 days. Furthermore, the antimicrobial of amoxicillin was demonstrated by antimicrobial activity assays, which are effective in treating Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus). The PCL/CS was enough for the bacterial inhibition growth of E. coli and S. aureus. The PCL/CS could be appropriate to supply a model the drug delivery system for the medical application.

Index Terms—polycaprolactone, chitosan, amoxicillin, microemulsion, antibacterial

I. INTRODUCTION

Amoxicillin is semi-synthetic of penicillin used for the treatment of gastric acid and antibacterial in the oral cavity [1]. It is executed to a patient at a dose of 250-500 mg every 8 hrs. after administration in the body. Amoxicillin is most effective during bacterial growth, both gram-positive (E. coli) and gram-negative (S. aureus and S. epidermidis) [2]. Amoxicillin is very well absorbed from the gastrointestinal tract. Amoxicillin is progressive absorbed from the gastrointestinal tract [3]. However, the half life of drug is 8 hrs. The clearance of amoxicillin is relatively quick in the body. As a consequence of the drug delivery system to prolong controlled drug release using the development of microparticles. Microparticles can be controlled drug release to safely achievement for desired therapeutic effects. Thus, the development of microparticles can be protected and controlled by the release of the drug for a limited time [4]. The microparticles were prepared from biopolymers such as proteins, polysaccharides, and synthetic polymers [5]. Biopolymers are biodegradable, biocompatible, non-toxic, low cost and easy to chemically modify. The microparticles were prepared using the emulsion technique for sustained drug delivery systems based on the encapsulation of drug and proteinaceous compounds [6], [7].

PCL is commonly used in biomedical applications due to its unique biocompatible, biodegradable structure and non-toxicity. It was approved by the FDA for medical applications and drug delivery systems [8]. It can be influenced by hydrolysis of the ester group and the degradation structure can eventually be metabolized or eliminated by the body. However, there are disadvantages including strong hydrophobicity [9]. Therefore, the efficiency of the drug maintains in PCL is lower than the hydrophilic group. The problem has been PCL modified with chitosan.

Chitosan is non-toxic, biodegradable and biocompatible [10]. Therefore, chitosan applied of biomedical field such as antibacterial agents, prolong for the release of protein and drugs [11]. Also, the combination of amoxicillin and chitosan can be reacted due to chitosan demonstrates antibacterial activity [12]. Although emulsion techniques are effective in drug stores, there are limitations might be a rapid release and the inability to control the release is maintained [13]. This work prepares PCL/CS microparticles by oil in water emulsion (o/w emulsion) techniques for inhibiting of antibacterial, leading to controlled release of amoxicillin for 7 days.
II. METHOD

A. Preparation of the Amoxicillin Loading-PCL/CS Microparticles

1) Materials
Polycaprolactone: PCL (Mw = 70,000-90,000 g/mol) and chitosan were purchased from Sigma-Aldrich (Singapore). Pol(vinyl alcohol): PVA (MW ~31,000 Da) were purchased from Sigma-Aldrich (USA). Acetone (A.R. grade) and dichloromethane (A.R. grade) were purchased from Lab-Scan (Asia) (Thailand). Amoxicillin (Trimox 500 mg) was purchased from Chumohon Pharmaceutical (Thailand). Di-Potassium hydrogen orthophosphate (Mw 174.18 g/mol) and potassium dihydrogen orthophosphate (Mw 136.09 g/mol) was purchased from Univar (Australia). All chemical agents were of analytical grade.

2) Fabrication of PCL Microparticles
PCL microparticles were fabricated using an o/w emulsion technique, containing 100 mg PCL powder was first dissolved in 3:1 mL of organic solvent (dichloromethane: acetone) [7]. Next, A solution of amoxicillin 100 mg/mL in deionized water was added 10 mL of an aqueous solution. The mixture was then polyvinyl alcohol (PVA) 0.5%w/v was added into 30 mL of emulsified under constant agitation by homogenizer (IKA RW 20 digital mechanical stirrer) at 8,000 rpm for 40 °C at 30 min [14] to obtain an o/w emulsion. Next, the emulsion was magnetically stirred for 5 hrs. at 45°C to evaporate organic solvent. Finally, the microparticles were obtained by centrifugation, washed three times with deionized distilled water and freeze dried (Lyoph – Pride series freeze dryer, IlShin).

3) Fabrication of Chitosan modified by PCL (PCL/CS) microparticles
Chitosan was modified by PCL (PCL/CS microparticles) were fabricated using an o/w emulsion technique, containing 100 mg PCL powder was first dissolved in 3:1 mL of organic solvent (dichloromethane: acetone). PCL microparticles were mixed by varying the chitosan concentrations of 100, 300 and 500 mg in acetic acid 1%w/v into 10 mL of an aqueous solution. The ratio of PCL/CS was 1:1, 1:3 and 1:5. Next, A solution of amoxicillin 100 mg/mL in deionized water was added into 30 mL of emulsified under constant agitation by homogenizer (IKA RW 20 digital mechanical stirrer) at 8,000 rpm for 40 °C at 30 min to obtain an o/w emulsion. Next, the emulsion was magnetically stirred for 5 hrs. at 45°C to evaporate organic solvent. Finally, the microparticles were obtained by centrifugation, washed three times with deionized distilled water and freeze dried (Lyoph – Pride series freeze dryer, IlShin).

B. Size and Surface Morphology Analysis
The morphology of PCL and PCL/CS 1:1, 1:3 and 1:5 microparticles was examined using a JEOL JSM 6400 Scanning Electron Microscope (SEM). The average diameter was analyzed with SemAfore 5.21 software.

C. Zeta Potential Measurement
The zeta potential of the microparticles was determined by dynamic light scattering technique (DLS, Malvern. Zetasizer Nano ZSP, UK). The microparticles were dispersed in distilled water. The zeta potential value is the average of three consecutive measurements.

D. Swelling Behavior
The swelling behavior of the control PCL and PCL/CS 1:1, 1:3 and 1:5 microparticles was examined by immersion in 10 mL of 10 mM Phosphate Buffered Saline (PBS) at 37 °C. After 24 hrs. the swollen microparticles were examined by Dynamic Light Scattering technique (DLS, Malvern. Zetasizer Nano ZSP, UK). The Swelling ratio was calculated using the following equation Equation (1) [15]:

\[
\text{Swelling ratio} = \left( \frac{D_{\text{swell}}}{D_{\text{dry}}} \right) \times 100
\]

where \(D_{\text{dry}}\) is the average diameter of dry microparticles; \(D_{\text{swell}}\) is the average diameter of microparticles swollen in buffer solutions after 24 hrs.

E. Encapsulation Efficiency
Amoxicillin loaded PCL and PCL/CS 1:1, 1:3 and 1:5 microparticles were prepared by magnetically stirred at room temperature. The percentages of the encapsulation efficiency was determined for each batch of PCL and PCL/CS 1:1, 1:3 and 1:5 microparticles. The amount of amoxicillin encapsulated in PCL/CS microparticles was measured by UV-Visible spectrophotometer at a wavelength of 273 nm. The percentages of the encapsulation efficiency was calculated using the following equation Equation (2) [13]:

\[
\text{% Encapsulation Efficiency} = \left( \frac{W_1}{W_0} \right) \times 100
\]

where \(W_1\) is the total milligram amoxicillin encapsulated at PCL/CS microparticles; \(W_0\) is the initial milligram amoxicillin loaded.

F. In Vitro Drug Release
Amoxicillin loaded PCL and PCL/CS 1:1, 1:3 and 1:5 microparticles were immersed into phosphate buffer solution pH 7.4 and left into the incubator at 37 °C. Sampling 3 mL of solution was taken out every 10 minutes until 7 days. In each time of sampling, 3 mL phosphate buffer were added into the solution. The release of amoxicillin from PCL and PCL/CS 1:1, 1:3 and 1:5 microparticles in phosphate buffer was determined by UV-VIS spectrophotometer (SPECORD® 210 PLUS) at a wavelength of 273 nm.

G. In Vitro Antibacterial Activity Assay
The strains of bacteria used in this research were Escherichia coli (ATCC 25922) and Staphylococcus aureus (ATCC 25923). The antibacterial activity was assessed by the agar well diffusion method (Muller-Hinton agar, Diag-Med, Poland). Molten nutrient agar (15 mL) was inoculated with 0.1 mL of test bacteria. Twenty µL of
the sample solution was filled in the well and incubated at 37°C for 24 hrs. The diameters [mm] of inhibition zone was then measured and compared with a disc containing 100 mg/mL of amoxicillin (control) [16].

III. RESULTS AND DISCUSSION

A. Morphology of Microparticles

Scanning electron micrographs of PCL and PCL/CS 1:1, 1:3 and 1:5 microparticles are showed the formation of spherical shape and a smooth surface but different sizes (Fig. 1 and Fig. 2). The average diameters of PCL microparticles are 1.093±0.37 µm. PCL was modified with the addition of chitosan in the o/w emulsion process had calculated mean diameters of PCL/CS 1:1, 1:3 and 1:5 are 1.464±0.58, 1.8230±0.49 and 2.249±0.75 µm, respectively. The average diameters of PCL/CS microparticles increased when the amount of chitosan increased in Fig. 2 [17] because the average diameters increase is due to the chitosan amount led to an increase of the viscosity, chain entanglement and opposite charge interaction between PCL and chitosan.

B. Zeta Potential of Microparticles

Zeta potential measurements of PCL and PCL/CS 1:1, 1:3 and 1:5 microparticles are presented in Fig.3a. The zeta potential of -22.96±0.43 mV of PCL microparticles is mainly derived from the negatively charged groups (carbonyl groups) on the backbone. The o/w emulsion process of PCL/CS 1:1, 1:3 and 1:5 resulted in zeta potential values of +15.23±0.09, +33.50±2.2 and +39.60±0.95 mV respectively, due to the positively charged amino groups of CS.

C. PCL and PCL/CS 1:1, 1:3 and 1:5 Microparticles Swelling Studies

The swelling ratios of the PCL and PCL/CS 1:1, 1:3 and 1:5 microparticles at pH 7.4 before and after swelling in phosphate buffer were studied at 37°C for 24 hrs. The diameters of dry and wet PCL and PCL/CS 1:1, 1:3 and 1:5 microparticles were determined and reported in Fig. 3b. The diameter of PCL, PCL/CS 1:1, 1:3 and 1:5 microparticles before and after swelling were 112.16±1.2, 232.99±0.46, 243.24±0.17 and 271.82±0.81µm, respectively. The swelling ratios increased with increasing the amount of CS due to the hydrophilicity [12].
D. Encapsulation Efficiency

The percentages of the encapsulation efficiency were determined amoxicillin in the microparticles as observed in Fig. 4.

E. Amoxicillin Released from PCL, PCL/CS 1:1, 1:3 and 1:5 Microparticles

The microparticles were immersed in 0.05 M phosphate buffer pH 7.4 and incubated in a shaking water bath at 37 °C with shaking at 70 rpm continues 7 days. The release profiles are paid as the percentages of the cumulative of amoxicillin released as presented in Fig. 5. The release rate of amoxicillin in microparticles was found that PCL microparticles provided a higher release rate more than PCL/CS microparticles because of PCL was lower of encapsulation efficiency, amoxicillin was released quickly within 12 hrs. PCL was modified surface with chitosan control the release within 7 days.

F. In Vitro Antibacterial Activity Assay of Microparticles

The in vitro antibacterial activity of the PCL, Chitosan, PCL loaded amoxicillin and PCL/CS 1:5 microparticles were profiled in vitro release provided biphasic modulation. The first day was characterized by a relatively rapid initial release and followed by the second day of a slower release [19]. PCL/CS 1:5 microparticles had the maximum amount of amoxicillin released 6.56± 0.03 mg, it can release of amoxicillin more than PCL/CS 1:1 and PCL/CS 1:3 was released at 5.76± 0.93 and 6.26± 0.05 mg, respectively for 7 days.

This result was shown that the swelling of PCL/CS at ratio 1:5 demonstrated the highest of 83.38±0.11% because the chitosan has a hydrophilic group, so the phosphate buffer diffuses into the particles can be easy. PCL/CS 1:5 microparticles were profiled in vitro release provided biphasic modulation. The first day was characterized by a relatively rapid initial release and followed by the second day of a slower release [19]. PCL/CS 1:5 microparticles had the maximum amount of amoxicillin released 6.56±0.03 mg, it can release of amoxicillin more than PCL/CS 1:1 and PCL/CS 1:3 was released at 5.76±0.93 and 6.26±0.05 mg, respectively for 7 days.

F. In Vitro Antibacterial Activity Assay of Microparticles

The in vitro antibacterial activity of the PCL, Chitosan, PCL loaded amoxicillin and PCL/CS 1:5 microparticles were profiled in vitro release provided biphasic modulation. The first day was characterized by a relatively rapid initial release and followed by the second day of a slower release [19]. PCL/CS 1:5 microparticles had the maximum amount of amoxicillin released 6.56±0.03 mg, it can release of amoxicillin more than PCL/CS 1:1 and PCL/CS 1:3 was released at 5.76±0.93 and 6.26±0.05 mg, respectively for 7 days.

The result was shown that the encapsulation efficiency of amoxicillin in PCL/CS 1:1, 1:3 and 1:5 microparticles was 74.35±0.23, 79.01±0.02 and 83.38±0.11%. This revealed that amoxicillin concentration increased when chitosan increased due to polyion complexation [18].

Polion complexes can be reacted electrostatic interactions between positively charged (the amino group of chitosan = +53.93±5.00 mV) and negatively charged (the carbonyl group of amoxicillin = -20.03±2.2 mV) species. So, that would promote electrostatic interaction between positive and negative charged molecules to maintain the release of drug from microparticles. While, the encapsulation efficiency of amoxicillin in PCL was 5.40±0.28% due to the PCL and amoxicillin were negatively charged. Therefore, PCL microparticles showed a lower encapsulation efficiency of the drug.

E. Amoxicillin Released from PCL, PCL/CS 1:1, 1:3 and 1:5 Microparticles

The microparticles were immersed in 0.05 M phosphate buffer pH 7.4 and incubated in a shaking water bath at 37 °C with shaking at 70 rpm continues 7 days. The release profiles are paid as the percentages of the cumulative of amoxicillin released as presented in Fig. 5. The release rate of amoxicillin in microparticles was found that PCL microparticles provided a higher release rate more than PCL/CS microparticles because of PCL was lower of encapsulation efficiency, amoxicillin was released quickly within 12 hrs. PCL was modified surface with chitosan control the release within 7 days.

This result was shown that the swelling of PCL/CS at ratio 1:5 demonstrated the highest of 83.38±0.11% because the chitosan has a hydrophilic group, so the phosphate buffer diffuses into the particles can be easy. PCL/CS 1:5 microparticles were profiled in vitro release provided biphasic modulation. The first day was characterized by a relatively rapid initial release and followed by the second day of a slower release [19]. PCL/CS 1:5 microparticles had the maximum amount of amoxicillin released 6.56±0.03 mg, it can release of amoxicillin more than PCL/CS 1:1 and PCL/CS 1:3 was released at 5.76±0.93 and 6.26±0.05 mg, respectively for 7 days.

F. In Vitro Antibacterial Activity Assay of Microparticles

The in vitro antibacterial activity of the PCL, Chitosan, PCL loaded amoxicillin and PCL/CS 1:5 microparticles were profiled in vitro release provided biphasic modulation. The first day was characterized by a relatively rapid initial release and followed by the second day of a slower release [19]. PCL/CS 1:5 microparticles had the maximum amount of amoxicillin released 6.56±0.03 mg, it can release of amoxicillin more than PCL/CS 1:1 and PCL/CS 1:3 was released at 5.76±0.93 and 6.26±0.05 mg, respectively for 7 days.

The result was shown that the encapsulation efficiency of amoxicillin in PCL/CS 1:1, 1:3 and 1:5 microparticles was 74.35±0.23, 79.01±0.02 and 83.38±0.11%. This revealed that amoxicillin concentration increased when chitosan increased due to polyion complexation [18].

Polion complexes can be reacted electrostatic interactions between positively charged (the amino group of chitosan = +53.93±5.00 mV) and negatively charged (the carbonyl group of amoxicillin = -20.03±2.2 mV) species. So, that would promote electrostatic interaction between positive and negative charged molecules to maintain the release of drug from microparticles. While, the encapsulation efficiency of amoxicillin in PCL was 5.40±0.28% due to the PCL and amoxicillin were negatively charged. Therefore, PCL microparticles showed a lower encapsulation efficiency of the drug.
that, PCL loaded amoxicillin, and PCL/CS 1:5 microparticles loaded amoxicillin in a liquid medium. Amoxicillin was able to inhibit both of bacterial growth (E. coli and S. aureus) at each studied concentration, while the bacterial inhibition of PCL and PCL/CS microparticles increased with the amount of amoxicillin released. This is likely due to the increased encapsulation efficiency of PCL/CS 1.5, which can be released amoxicillin in antibacterial [20].

![Figure 6. Growth inhibition of Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) after treatment with PCL, Chitosan, amoxicillin (100 mg/mL), PCL loaded amoxicillin and PCL/CS 1:5 microparticles loaded amoxicillin for 24 hrs. at 37 °C in liquid medium.](image)

### IV. CONCLUSION

The PCL microparticles modified surface with chitosan were prepared by oil in water emulsion (o/w emulsion) techniques. The PCL/CS at ratio 1:5 containing amoxicillin presented the %EE of 83.38±0.11%. The maximum release profile was 6.56±0.03 mg within 7 days. Moreover, The bacterial inhibition growth of E.coli and S. aureus can be antibacterial of 17.23 mm and 25.90 mm, respectively. This could be appropriate to provide the model drug delivery system for the medical application.

### CONFLICT OF INTEREST

The authors declare no conflict of interest.

### AUTHOR CONTRIBUTIONS

C. Methheeparakornchai performed the experiment, modified microparticles, analyzed the data; and co-wrote the paper; N. Kreua-ongarjnkool and S. T. Niyomthai conceived the study and were in charge of overall direction and planning, processed the experimental data, co-wrote the paper, visualization, reviewing and editing; P. Pavasant and C. L. Nakalekha had conceptualization, reviewing and editing for in vivo antibacterial activity assay; all authors commented on the paper and had approved the final version submitted for publication.

### ACKNOWLEDGMENT

The authors would like to express sincere thanks to Science and Technology Research Institute for financial support from Science and Technology (grants No. KMUTNB-62-DRIVE-036). Special thanks to Graduate College and Industrial Chemistry Department, Faculty of Applied Science, King Mongkut's University of Technology North Bangkok for their supporting.

### REFERENCES

[1] A. K. Kęsiuk, A. Nosol, J. Ponka, M. S. Matuszowsicz, M. G. Cepa, M. K. Borkowicz, et al., “PLGA-Amoxicillin-loaded layer formed on anodized Ti alloy as a hybrid material for dental implant applications,” Mater Sci. Eng. C. Mater Biol. Appl., vol. 94, pp. 998-1008, 2019.

[2] I. J. B. I. D. Brook, “The role of beta-lactamase-producing bacteria in mixed infections,” BMC. Infect. Dis., vol. 9, no. 1, p. 202, 2009.

[3] G. Delage, F. Boucher, H. D. Davies, J. Embree, C. Morin, D. Speert, et al., “High dose amoxicillin: Rationale for use in otitis media treatment failures,” Tij. Paediatr Child Health., vol. 10, no. 4, pp. 277-278, July 1999.

[4] M. Tatullo, M. Marrelli, F. Mastrangelo, and E. Gherlone, “Bone inflammation, bone infection and dental implants failure: Histological and cytological aspects related to cement excess,” J. Bone Jt. Infect., vol. 2, no. 2, pp. 84-89, January 2017.

[5] B. Azimi, P. Nourpanah, M. Rabiee, and S. Arbab, “Producing gelatin nanoparticles as delivery system for bovine serum albumin,” Iran Biomed., vol. 18, no. 1, p. 34, January 2014.

[6] B. B. C. Youan, M. A. Benoit, B. Baras, and J. Gillard, “Protein–loaded poly (episol–caprolactone) microparticles. I. Optimization of the preparation by (water–in–oil)–in water emulsion solvent evaporation,” J. Microencapsulation., vol. 16, no. 5, pp. 587-599, 1999.

[7] N. Soomherun, N. Kreua-ongarjnkool, S. Chumnanvej, and S. Thumsing, “Encapsulation of nicardipine hydrochloride and release from biodegradable poly(D,L-lactic-co-glycolic acid) microparticles by double emulsion process: Effect of emulsion stability and different parameters on drug entrapment,” Int. J. Biomater., vol. 2017, article ID 1743765, 2017.

[8] M. A. Woodruff and D. W. Hutmacher, “The return of a forgotten polymer—Poly(caprolactone) in the 21st century,” Prog. Polym. Sci., vol. 35, no. 10, pp. 1217-1256, 2010.

[9] J. Yan, Y. Zhang, Y. Xiao, Y. Zhang, and M. Lang, “Novel poly (ε-caprolactone) bearing amino groups synthesis, characterization and biotinylation,” REACT FUNCT POLYM., vol. 70, no. 7, pp. 400-407, July 2010.

[10] N. A. Dzung, N. T. N. Ha, D. H. Van, N. T. L. Phuong, N. T. N. Quynh, D. H. Heip, et al., “Chitosan nanoparticles as a novel delivery system for A/H1N1 influenza vaccine: Safe property and immunogenicity in mice,” World Acad. Sci. Eng. Technol., vol. 60, pp. 1839-1846, January 2011.

[11] E. Onuigbo, A. Onugwu, M. Nwocha, A. Dzung, N. Hà, D. Trang, and J. Kreuter, “Comparison of methods for the determination of amoxicillin in capsules and tablets: Rationale for use in otitis media treatment failures,” Int. J. Pharm., vol. 998, pp. 799-804, January 2010.

[12] G. Delage, F. Boucher, H. D. Davies, J. Embree, C. Morin, D. Speert, et al., “High dose amoxicillin: Rationale for use in otitis media treatment failures,” Tij. Paediatr Child Health., vol. 10, no. 4, pp. 277-278, July 1999.

[13] B. Azimi, P. Nourpanah, M. Rabiee, and S. Arbab, “Producing gelatin nanoparticles as delivery system for bovine serum albumin,” Iran Biomed., vol. 18, no. 1, p. 34, January 2014.

[14] B. B. C. Youan, M. A. Benoit, B. Baras, and J. Gillard, “Protein–loaded poly (episol–caprolactone) microparticles. I. Optimization of the preparation by (water–in–oil)–in water emulsion solvent evaporation,” J. Microencapsulation., vol. 16, no. 5, pp. 587-599, 1999.

[15] N. Soomherun, N. Kreua-ongarjnkool, S. Chumnanvej, and S. Thumsing, “Encapsulation of nicardipine hydrochloride and release from biodegradable poly(D,L-lactic-co-glycolic acid) microparticles by double emulsion process: Effect of emulsion stability and different parameters on drug entrapment,” Int. J. Biomater., vol. 2017, article ID 1743765, 2017.

[16] M. A. Woodruff and D. W. Hutmacher, “The return of a forgotten polymer—Poly(caprolactone) in the 21st century,” Prog. Polym. Sci., vol. 35, no. 10, pp. 1217-1256, 2010.

[17] J. Yan, Y. Zhang, Y. Xiao, Y. Zhang, and M. Lang, “Novel poly (ε-caprolactone) bearing amino groups synthesis, characterization and biotinylation,” REACT FUNCT POLYM., vol. 70, no. 7, pp. 400-407, July 2010.

[18] N. A. Dzung, N. T. N. Ha, D. H. Van, N. T. L. Phuong, N. T. N. Quynh, D. H. Heip, et al., “Chitosan nanoparticles as a novel delivery system for A/H1N1 influenza vaccine: Safe property and immunogenicity in mice,” World Acad. Sci. Eng. Technol., vol. 60, pp. 1839-1846, January 2011.

[19] E. Onuigbo, A. Onugwu, M. Nwocha, A. Dzung, N. Hà, D. Trang, and J. Kreuter, “Comparison of methods for the determination of amoxicillin in capsules and tablets: Rationale for use in otitis media treatment failures,” Int. J. Pharm., vol. 998, pp. 799-804, January 2010.
Chalita Metheeparakornchai was born in Thailand, in 1995. She is a graduate of Bachelor of Science degree since 2017. She is studying in the Master of Science degree from Industrial Chemistry Department, Faculty of Applied Science, King Mongkut’s University of Technology North Bangkok, Thailand. Her research fields are biopolymer, material science, and drug delivery system. She got to research grants from Science and Technology Research Council of Thailand (Grants: KMUTNB-62-DRIVE-036).

Narumol Kreua-ongjunkruool was born in Bangkok, Thailand, in 1960. She received the second class honors degree in the Bachelor Degree in Chemistry from Srinakharinwirot University and Master of Science degree in Chemistry from the Department of Chemistry, Faculty of Science, Chulalongkorn University. She is an Associate Professor at the Department of Industrial Chemistry, Faculty of Applied Science, King Mongkut’s University of Technology North Bangkok. She is the secretary of Chemical Society of Thailand under the Patronage of Her Royal Highness Princess Chulabhorn Krom Phra Sri savangkavadhana. She received the outstanding research advisor award in 2017 from graduate school, KMUTNB. She has been joining the research to develop nanocarriers for drug delivery of in intraoperative Cerebrovascular Surgery at the Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand since 2013. Her research interests include the fields of material science, micro/nano-encapsulation for biomedical application, biopolymer for drug delivery system, and wound dressings materials. She recently received the most outstanding employee award 2018 from KMUTNB. She has published the research paper in the various journals and in the proceedings of the international conferences.

Prasit Pavasant is a graduate in Doctor of Dental Surgery at Chulalongkorn University since 1985. He holds a Ph.D. degree in biomedical engineering from Georgetown University of the United States of America since 1995. He is a Professor at the Department of Anatomy, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand. His research fields are Bone biology, tissue culture, Biomedical Science, Gross anatomy, Histology, Neuroanatomy, Oral Histology and Embryology. He recently received the National Outstanding Researcher of the Year 2017 in the award of Medical Science from the National Research Council of Thailand.

Chalida Limjeerjaruk Nuakaleka is a graduate in Doctor of Dental Surgery Degree at Chulalongkorn University since 2004. She trained in Research and Clinical Student, Department of Fixed Prosthodontics from Tokyo Medical and Dental University since 2006. She holds a Ph.D. degree in Dental Sciences from the Department of Cellular Physiological Biochemistry at Tokyo Medical and Dental University since 2010. She is an Assistant professor at the Department of Physiology, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand. Her research fields are cell biology, tooth biomechanics, drug delivery system, regenerative endodontics, molecular biology. She recently received the research presentation contest at the Dental Faculty Consortium of Thailand in 2018.